PR97753

TEL AVIV, Israel, Sept. 13, 2022 /PRNewswire=KYODO JBN/ --

Microtech, a wholly owned subsidiary of Medinol, Inc., a leader in global

MedTech research and development, announced that its implantable microsensor

platform will be presented at the 34th Transcatheter Cardiovascular

Therapeutics (TCT), the annual scientific symposium of the Cardiovascular

Research Foundation on Friday, September 16.  A prestigious selection, this

session will highlight a limited number of cutting edge technologies important

to advancing cardiovascular treatment.  Microtech is honored to be selected as

one of the organizations participating.

Logo - https://mma.prnewswire.com/media/1895526/Medinol_Logo.jpg

Microtech implantable microsensor platform is the culmination of decades of

development in a new class of sensor technology that can be used not only as a

stand-alone device but can also be integrated onto any existing device turning

it from treatment only to smart, data gathering devices able to perform

multiple functions at once.

The session entitled, "Microsensors: Turning Implantable Devices Into Real-Time

Physiologic Monitors (Microtech)," will feature a procedure showing a device

incorporating Microtech implantable microsensor platform implanted in the left

atrium for the ongoing assessment of Heart Failure. In addition to the case

presentation, Dr. Yoram Richter Ph.D., CEO of Medinol Ltd, will be presenting

the technology platform followed by a Q/A with the invited panel and a

roundtable discussion.

"Adding sensors to existing medical devices gives physicians the ability to

treat patients based on quantifiable physiological parameters instead of

symptoms and is a critical step to growing access to equitable healthcare

across the global community. Using a compact home unit, a patient with

Microtech implantable microsensor platform can deliver immediate and highly

accurate pressure readings directly to their physician turning geographical

distance or mobility challenges into a non-issue," says Dr. Yoram Richter.  

"Since Microtech implantable microsensor platform can be used for widely

varying scenarios including patients suffering from Heart Failure, Glaucoma,

Hydrocephalous, Portal Hypertension, AAA Endoleaks and many more, the

integration, adoption and implantation of this innovative platform will provide

wider healthcare access and fewer office/hospital visits. From the standpoint

of treating clinicians and device manufacturers, sensor enabled devices will go

beyond acute anatomical fixes, extending treatment to lifetime patient care."

About Medinol

At Medinol, we are aggressively changing paradigms in how disease states are

diagnosed and treated.  Whether designing cutting edge devices for stenting

multiple areas of the body, dramatically reducing complications in Structural

Heart procedures or providing real time insights into the physiological metrics

of the human body through implantable sensors, we boldly reassess current

technology and procedures and look years into the future to pioneer new devices

to broaden the reach of physicians both physically and geographically.  Working

with our physician and industry partners, Medinol is creating the future today.

For more information see www.medinol.com or contact Jeff Roach, Chief

Commercial Officer at JeffR@medinol.com.

SOURCE Medinol